Assessment Of Duration Of Action, Safety & Toleration Of UK369,003 and Cialis In Patients With Erectile Dysfunction

Pfizer300 enrolled

Overview

Assessment of duration of action, safety \& toleration of different formulations and doses of UK-369,003 and Cialis in patients with male erectile dysfunction. Patients should have previously been on PDE5 inhibitors and have been respondents to the drug. Duration of treatment is 4 weeks.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

300

Conditions

Impotence

Interventions

UK0369,003DRUG

Cialis (Tadalafil)DRUG

Eligibility

Sex: MALEMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Erectile Dysfunction Exclusion Criteria: * Alpha blockers and Nitrates of any preparation

Outcomes

Primary Outcomes

Assessment of duration of action, safety & toleration of the investigational drug and Cialis

Secondary Outcomes

Assess safety & toleration over 4 week treatment period

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.